INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Site Selection & Management

Strategic site selection for dermatology and rheumatology clinical trials, based on relevant experience in your indication, positive indicators in efficacy assessments, and proven recruitment track records.

Investigators in Our Database (& Growing)

2975 +
 Years of Experience
1 +
Clinical Trials
475 +

Dermatology & Rheumatology Site Selection

By carefully selecting the right sites for your clinical trial, sponsors can expect reliable data, timely recruitment, and cost-effective study management. Indero’s team of site selection specialists is always working on finding the best sites to increase our extensive dermatology and rheumatology site database. Here’s how we work:

(1) Site List 

  • Evaluate your study protocol with a cross-functional team to fully understand site requirements and core competencies.
  • Develop site selection strategy, including recruitment objectives and projections based on competitive landscape, timelines, and sites’ past performance metrics.
  • Create a site list and an initial expression of interest.

 

(2) Site Outreach

  • Conduct a pre-feasibility assessment.
  • Pre-identify the most suitable sites and anticipate potential challenges.
  • Develop feasibility questionnaire based on pre-feasibility and study protocol.
  • Evaluate expected site performance.

(3) Site Qualification Visit (SQV) 

  • Define type of SQV based on specific study requirements and selection strategy.
  • Evaluate FQ and site qualifications to determine if a CRA should conduct an SQV for that site (onsite or remote).
  • Provide feedback based on SQV.

 

 

 

(4) Site Selection 

  • Receive CRA recommendations within 24–48 hours of the SQV, with final recommendation for selection (or not) from a site selection specialist.
  • Fast track designation can be applied to sites whom Indero has worked with in the last 12 months, accelerating selection and lowering costs (no SQV required).
  • Site selected with sponsor approval.

Site Selection Criteria

Experience

Sites that have successfully performed studies in your indication of interest.

Performance

Sites with high-quality indicators in efficacy assessments and overall study performance.

Recruitment

Sites with an extensive patient database and a proven track record of on-time recruitment.

Snehal Naik, PhD

Senior Vice President, Clinical Development
Ventyx Biosciences, Inc.

“. . . From the initial synopsis development to the final stages of study conduct, the synergy between our teams was palpable and was underpinned by Indero’s strong relationships with sites, investigators, and KOLs. . .”

Key Success Factors of Site Selection

With customized and consolidated outreach processes, Indero offers efficient and expedited site selection timelines. Here’s what makes our site selection and management services so successful:

  • Competitive global budget: Including a grant plan or global fair market value (FMV)
  • Site list optimization: Matching pre-feasibility to interest, expertise, and capabilities
  • Personalized outreach: Tailoring approach for first contact
  • Easy contracting: Utilizing existing CDA template to avoid new contracting for sites with existing agreement
  • North American and European presence: Utilizing local team members and languages
  • Established relationships: Capitalizing on established key opinion leaders and site network relationships

Partner with Indero for Site Selection & Management

Indero is a dual-focus CRO for dermatology and rheumatology clinical trials that identifies, qualifies, and selects the most suitable sites for successful studies.

Let’s talk

Site Selection & Management Services that Accelerate Studies

Scientific discipline. Operational efficiency. Clinical development expertise. Our site selection and management services provide the rigorous foundation, quality data, and expertise dermatology and rheumatology studies need to ensure effective execution and on-time delivery.

ABOUT INDERO

“My work experience with Indero has been very positive. Their monitoring support has been crucial in achieving our research goals. So far, this partnership is a true success story. Their professionalism and expertise are commendable.”

Assoc Prof. Beata Imko-Walczuk

Copernicus Medical Center, Gdansk

Wherever
You’re Going,
We’re all in.

Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.

Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >